Last reviewed · How we verify
Sustiva
At a glance
| Generic name | Sustiva |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Target | Cholesterol 24-hydroxylase, ATP-binding cassette sub-family G member 2, Nuclear receptor subfamily 1 group I member 2 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Human immunodeficiency virus infection
Common side effects
- Rash
- Nausea
- Vomiting
- Dizziness
- Headache
- Fatigue
- Insomnia
- Pain
- Diarrhea
- Dyspepsia
- Abdominal pain
- Anxiety
Key clinical trials
- The T Cell Activator of Cell Killing ("TACK") IT ON" STUDY (NA)
- Pharmacologic Strategies to Use the Levonorgestrel Implant in HIV-infected Women (PHASE2)
- EFV Pharmacokinetics & Pharmacogenomics in Older HIV-infected Patients
- A Pharmacokinetic Evaluation of Levonorgestrel Implant and Antiretroviral Therapy (PHASE2)
- Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants (PHASE2)
- Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection (PHASE1, PHASE2)
- Efavirenz for Patients With Alzheimer's Disease (PHASE1)
- The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |